NovoCure Limited (NVCR), Monday announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua, authorized for use in adult patients with unresectable advanced/recurrent non-small cell lung cancer or NSCLC.
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields, which exerts physical forces on the electrically charged components of dividing cancer cells, resulting in cancer cell death.
The reimbursement, through the country's National Health Insurance coverage, provides patients with advanced NSCLC access to Optune Lua as a treatment option at qualified health centers.
In the pre-market hours, NVCR is trading at $13.46, down 1.54 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.